Member Profile

Dr. Margareth Ozelo

Dr. Margareth Ozelo has developed and currently runs a large hemophilia reference center that cares for over 800 patients (400 hemophilia patients). She acts as the director of a WFH designated International Hemophilia Training Center and as a consultant for Brazilian Ministry of Health on matters that relate to patient care through the use of coagulopathies and inherited bleeding disorders. Dr. Ozelo has over 100 peer- reviewed publications and has participated in numerous clinical trials. She serves on an abundance of various international and regional groups focused on hemophilia care. Dr. Ozelo is committed to training other teams in respect to hemophilia.

Key Publications

-      Feldberg G, Ricciardi JBS, Zorzi A, Colella MP, Ozelo MC. Aquatic exercise in patients with haemophilia: electromyographic and functional results from a prospective cohort study. Haemophilia 2021 Mar;27(2):e221-e229.

-      Connell NT, Flood V, Abdul-Kadir R, Arapshian A, Couper S, Grow J, Kouides P, Laffan M, Lavin M, Leebeek F, O’Brien S, Ozelo MC, Tosetto A, Weyand A, Kalot M, Husainat N, Brignardello-Petersen R, Mustafa RA. ASH ISTH NHF WFH 2020 Guidelines on the Management of von Willebrand Disease. Blood Advances 2021 12 January 2021; Vol 5 (1): 301-325

-      Srivastava A, Santagostino E, Dougall A, and on behalf of the WFH Guidelines for the Management of Hemophilia panelists and co-authors (including Ozelo MC). WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;00:1–158

-      George LA, Ragni MV, Rasko JEJ, Raffini LJ, Samelson-Jones BJ, Ozelo M, Hazbon M, Runowski AR, Wellman JA, Wachtel K, Chen Y, Anguela XM, Kuranda K, Mingozzi F, High KA. Long-Term Follow-Up of the First In Human Intravascular Delivery of AAV For Gene Transfer: AAV2-hFIX16 For Severe Hemophilia B. Mol Ther. 2020 Sep 2;28(9):2073-2082.

-      Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016 May;14(5):1105-9.

Current Positions/Chairs:

  • Assistant Professor
    Department of Internal Medicine, Faculty of Science of Medicine University of Campinas, Brazil
  • Director
    IHTC, UNICAMP, Brazil
  • Consultant for the Program of Coagulopathies and other Inherited Bleeding Disorders
    Brazilian Ministry of Health
  • Director of Hematology and Transfusion Medicine Discipline
    Department of Internal Medicine, School of Medical Sciences, University of Campinas, Brazil

Key Institutions

  • University of Campinas
    Department of Internal Medicine
  • International Haemophilia Training Centre
    Hemocentro UNICAMP

Research Interests

  • Dr Ozelo is involved with several research projects, including gene therapy, risk factors for inhibitor development for factor VIII, immune tolerance induction, musculoskeletal outcomes and complications in hemophilia, and inherited platelet disorders.


  • Early Career Investigator Award – Bayer Hemophilia Awards Program (2003)
  • ZLB Behring - Grant for Hemophilia (2005)
  • CSL Behring – Prof. Heimburger Award (2010)
  • Novo Nordisk Haemophilia Foundation, MSK status for PWH in Brazil (2010)
  • Research Foundation of the São Paulo State (FAPESP) (2006) (2013) (2015)
  • Investigator Initiated Research Grant (IIRG) Baxalta-Shire, ProPK-Brazil (2016)
  • National Counsel of Technological and Scientific Development (CNPq) (2017)
  • Investigator Initiated Research Grant (IIRG) Pfizer, MSK-Brazil (2017)
  • Institutional Internationalization Program (CAPES-Print) (2018)
  • Investigator Initiated Research Grant (IIRG) Baxalta-Shire, BraSIL-rFVIII: Brazilian Study of Inhibitor Linked to recombinant factor VIII (2018)
  • Investigator Initiated Research Grant (IIRG) Roche, Low-dose ITI emicizumab (2021)